Day: December 10, 2021

6th indication for toripalimab submitted in China

SHANGHAI, China, Dec. 10, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has accepted the company’s supplemental New Drug Application (“sNDA”) for toripalimab in combination with chemotherapy as the first-line treatment of patients with treatment-naive advanced or metastatic non-small cell lung cancer (“NSCLC”) with no EGFR or ALK tumor aberrations.

The sNDA is based on the CHOICE-01 study (NCT03856411), which is the first domestic randomized, double-blind, placebo parallel-controlled, multi-center, Phase III study of an anti-PD-1 monoclonal antibody in combination with chemotherapy as first-line treatment that recruits both histological types of advanced squamous and non-squamous NSCLC. Professor Jie Wang from Cancer Hospital, Chinese Academy of Medical Sciences is the leading principal investigator for the study. The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients. Based on the interim analysis results of the CHOICE-01 study, the Independent Data Monitoring Committee (IDMC) determined that the primary endpoint of progression-free survival (“PFS”) has crossed the pre-defined efficacy boundary. The result of the study was presented during the Oral Session (abstract number MA13.08) at the 2021 World Conference on Lung Cancer (WCLC), showing that compared with chemotherapy alone, toripalimab in combination with chemotherapy as the first-line treatment for advanced NSCLC significantly prolonged the PFS of patients, reduced the risk of disease progression, and showed a positive trend in terms of overall survival (“OS”).

Junshi will submit further analysis of the results of OS of the CHOICE-01 study to the NMPA subsequently on a rolling basis and communicate with the US Food and Drug Administration (the “FDA”) on the same matter.

About NSCLC
Lung cancer is currently the second most prevalent malignant tumor with the highest mortality rate in the world, and the most prevalent with the highest mortality rate in China. According to data released by the World Health Organization, in 2020, the number of new lung cancer cases in China was estimated to be 816,000 and accounted for 17.9% of all new cancer cases in China. In the same year, the number of lung cancer deaths in China amounted to 715,000 and accounted for 23.8% of all cancer deaths. NSCLC is a major subtype of lung cancer, accounting for approximately 85% of all cases. Existing domestic and overseas studies have shown that monotherapy or combination chemotherapy of anti-PD-(L)1 monoclonal antibody has already become new standard for the first-line treatment of NSCLC.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells. More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI^®). On December 17, 2018, toripalimab was granted a conditional approval by the National Medical Products Administration (NMPA) for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (“NPC”) after failure of at least two lines of prior systemic therapy. In April, the NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. In November 2021, the NMPA approved toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma. In addition, the supplemental NDA for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma was accepted by the NMPA for review in July 2021.

In December 2020, toripalimab was successfully included in the updated National Reimbursement Drug List for the indication of the second-line treatment of unresectable or metastatic melanoma. In December 2021, two additional indications were included on the list: recurrent or metastatic nasopharyngeal carcinoma after failure of at least two lines of prior systemic therapy and locally advanced or metastatic urothelial carcinoma after failure of platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

In the United States, the FDA has granted priority review for the toripalimab BLA for the treatment of recurrent or metastatic NPC, an aggressive head and neck tumor which currently has no FDA-approved immuno-oncology treatment options. Earlier, the FDA granted Breakthrough Therapy designation for toripalimab in combination with chemotherapy for the 1st line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and orphan drug designation for esophageal cancer, NPC, mucosal melanoma and soft tissue sarcoma. Earlier in 2021, Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada. Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in more than 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

JD employees working on the rooftop of a JD warehouse

JD.com pioneered a rooftop distributed solar PV system in its Shanghai Asia No.1 in 2017, which now generates 3.11 million kWh per year, supplying the energy for warehouse lighting, automatic sorting, packaging, picking and other activities. Currently, JD has already finished installing PV systems at 12 logistics parks.

BEIJING, Dec. 10, 2021 (GLOBE NEWSWIRE) — JD.com is making progress in its construction of the first carbon-neutral intelligent industrial park for China’s logistics industry, with the Xi’an Asia No.1 logistics park expected to be carbon-neutral on the operations level by early 2022.

At nearly 300,000 square meters, JD’s Asia No.1 logistics park in Xi’an has deployed 100,000 square meters of rooftop solar PV with a capacity of 9 MW, which generated a total amount of about 8,500 MWh of electricity from January to October in 2021 — equivalent to providing electricity for about 3,900 Chinese households for a year, and reducing carbon emissions by approximately 5,670 tons when compared to purchasing electricity from local power plants.

JD’s new energy vehicle

Green transportation: 12,000 new energy vehicles reducing 120,000 tons of CO2 emissions per year. Over the past four years, JD has placed nearly 12,000 new energy vehicles in more than 50 cities across China and introduced more than 1,600 charging terminals, which can reduce up to 12,000 tons of CO2 emissions each year. JD Logistics is also the first logistics company in China to introduce the use of hydrogen-energy vehicles, which have been put into use in Shanghai, Guangzhou, and Foshan. In addition, by optimizing the warehousing network and transportation routes, JD can reduce the number of vehicles in transit, improve the full-load rate of round-trip vehicles and reduce vehicle waiting time.

In addition, Xi’an Asia No.1 can meet heating needs through distributed air conditioning instead of a conventional boiler room in certain areas. New energy is widely used in forklifts and other special equipment, including 22 sets of charging terminals that can support charging 44 vehicles at a time. Streetlights in the park will also gradually be replaced by solar lights. With the support of advanced technologies including 5G, blockchain and AI, JD is also researching an industry solution for carbon neutral parks by further improving operating efficiency and lowering energy consumption.

Green warehousing: Automation enabling warehouses to operate without lighting

JD.com pioneered a rooftop-distributed solar PV system in its Shanghai Asia No.1 location in 2017, which now generates 3.11 million kWh per year, supplying the energy for warehouse lighting, automatic sorting, packaging, picking and other activities. Currently, JD has completed installation of PV systems at 12 logistics parks, while automation systems and robots also enable warehouses to operate without lighting. Such “dark operations” help save an average of 2,283 kWh per minute at JD’s logistics parks, which is equivalent to the electric consumption of a normal household for one and a half years.

According to forecasts, the total production capacity of JD’s PV system will reach 100 MW by the end of 2021, which could provide energy for 50,000 households in a year. And in three years, the capacity is estimated to reach 1,000 MW — contributing green energy to 85% of JD’s intelligent industrial parks.

Green packaging: Saving 400 million meters of tape a year

In 2015, JD.com proposed the concept of “Slim Tape,” which cut the width of packing tape from 53 mm to 45 mm and helped reduce 400 million meters of tape in 2020 – an amount that can circle the equator 10 times. Now, “Slim Tape” has been made standard for China’s postal industry and used in external logistics enterprises.

As early as 2015, JD.com also began to use reusable cold chain boxes for fresh produce business, making it the first e-commerce company in China to adopt reusable packaging. As a result: 180 million disposable foam boxes were saved from waste from 2015 to 2020. The reusable Green Stream Box, which can be used 50 times, was later introduced and has been widely used in over 30 cities in China.

JD also initiated China’s E-commerce & Logistics Packaging Standards Alliance and worked with brands to redesign e-commerce goods’ original packaging to prevent transportation damage and reduce the need for repackaging. As of now, brands including P&G, Unilever and others have reduced their use of logistics cartons and paper by 150 million pieces and 125,000 tons, respectively.

Green transportation: 12,000 new energy vehicles reducing 120,000 tons of CO₂ emissions per year

Over the past four years, JD has placed nearly 12,000 new energy vehicles in more than 50 cities across China and introduced more than 1,600 charging terminals, which can reduce up to 120,000 tons of CO₂ emissions each year. JD Logistics is also the first logistics company in China to introduce a fleet of hydrogen-energy vehicles, which have been put into use in Shanghai, Guangzhou and Foshan. In addition, by optimizing the warehousing network and transportation routes, JD can reduce the number of vehicles in transit, improve the full-load rate of round-trip vehicles and reduce vehicle waiting time.

JD.com strives to build a green and low carbon business model and is leveraging its core competencies to continuously decrease its carbon footprint and operate a cleaner supply chain system.

About JD.com
JD.com is a leading supply chain-based technology and service provider. The company’s cutting-edge retail infrastructure seeks to enable consumers to buy whatever they want, whenever and wherever they want it. The company has opened its technology and infrastructure to partners, brands and other sectors, as part of its Retail as a Service offering to help drive productivity and innovation across a range of industries.

Media Relations
+86 (10) 8911-6155
Press@JD.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f60e8d4f-5268-41df-97b4-279d84aea97e

https://www.globenewswire.com/NewsRoom/AttachmentNg/21b1a909-5cb2-4c36-b66e-96d52d598433

The photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Unifty

Unifty

LONDON, Dec. 09, 2021 (GLOBE NEWSWIRE) — Unifty is marrying DeFi and NFTs with the launch of The Gallery, an innovative exhibition space inspired by the platform’s desire to improve upon the traditional gallery-creator relationship. The Gallery’s unique approach to the NFT marketplace means that all participants, including creators, collectors, curators, and fans, are rewarded for engaging on the platform.

The Gallery is both a reimagining of the way creators traditionally showcase their art to the public as well as a reimagining of the NFT platform experience. Through The Gallery, Unifty is ushering decentralized finance (DeFi) into the digital art exhibition and viewing process by rewarding and involving all community participants: from creators, collectors, art lovers, to organizations.

Initially, creators will be able to hold exhibitions in The Gallery for 30 days. Through their NFT exhibitions, they have the opportunity to sell their work, but in a unique twist are guaranteed a yield from simply hosting visitors to their collections.

Collectors, similarly, can hold exhibitions of their NFT collections and earn a yield. Unifty community members who visit the exhibitions also earn from their participation as art lovers. Much like DeFi, the ecosystem rewards participants no matter what their role is on the platform.

The Gallery’s aim is to both rectify the inherent imbalances in the creator-gallery relationship and to elevate the experience of engaging in the NFT landscape through the use of DeFi-type incentives.

How does it work?

Unifty is leveraging its dual-token structure to reward all participants in its ecosystem. $NIF tokens are the platform’s governance token. Holders of $NIF are able to vote on which creators or collectors are chosen to exhibit in The Gallery and vote more generally on the direction of the platform.

Token holders can also stake $NIF to those exhibitions they like. By staking $NIF, community members share earnings in the yield that the exhibition to which they stake generates. That yield is determined by a number of factors, including the agreed market value of the NFTs exhibited, the reputation of the creator, the number of $NIF tokens staked to it, and the number of individual stakers.

Rewards are paid out in Unifty’s reward token, $UNT. The $UNT that is farmed from a particular exhibition in The Gallery is paid out to the exhibitor – whether a collector or a creator – and those fans who staked $NIF to it.

Unifty, in this way, hopes to enhance the world of NFTs through instruments more commonly found in DeFi. Not only do creators get fairly rewarded for their work, through sales and/or through simply exhibiting it, but those who believe in and appreciate their work also earn a yield by staking their loyalty to the work they like, via $NIF tokens.

Unifty’s unique staking and rewarding system promises to enhance the digital art experience by engaging all participants through DeFi incentive and engagement mechanisms.
The Gallery launches on Dec. 9, 2021.
To learn more about Unifty, visit:

Official website: https://unifty.com

Gallery website: https://unifty.gallery

Twitter: https://twitter.com/unifty_com

Telegram Channel: https://t.me/unifty

Email: hello@unifty.com

Related Images

Image 1: Unifty

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Unifty